VolitionRx scores EU approval for prostate cancer test; MDxHealth inks coverage deal;

> VolitionRx ($VNRX) nabbed a CE mark for its blood-based prostate cancer test. More

> Belgium's MDxHealth inked a deal with Tufts Health Plan to provide its prostate cancer test for the insurer's 1 million members. Statement

> U.K. diagnostic outfit Premaitha Health is expanding outside Europe, inking a deal with Chile's Servicios Genéticos (OriGen) to offer its noninvasive prenatal screening test in the country. Statement

> T2 Biosystems ($TTOO) is touting a new study which shows increased sensitivity of its T2Candida panel compared to a traditional blood culture. More

> Transgenomic ($TBIO) and Australia's University of Melbourne are teaming up to develop the former's liquid biopsy technology. Release

And Finally… Scientists are using a DNA sequencer the size of a chocolate bar to track Ebola outbreaks. Story